Difference between revisions of "Stem cell mobilization regimens"
Warner-admin (talk | contribs) m (Text replacement - "#66CCFF" to "#deebf6") |
Warner-admin (talk | contribs) m (Text replacement - "font-size:200%"> Hello!<br> We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br> Please help us by filling it out!<br>" to "font-size:300%"> Just 10 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br>") |
||
Line 1: | Line 1: | ||
{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | {|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | ||
| | | | ||
− | <span style="font-family:Arial; font-size: | + | <span style="font-family:Arial; font-size:300%"> Just 10 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br> |
− | |||
− | |||
'''Link:''' http://j.mp/2BlBaoQ | '''Link:''' http://j.mp/2BlBaoQ | ||
</span> | </span> |
Revision as of 04:19, 23 January 2018
Just 10 days left to fill out a survey on how we can make HemOnc.org better and more useful. |
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Section editor | |
---|---|
Aric C. Hall, MD Madison, WI Twitter: AricHall1 |
Unlike the other chemotherapy regimen pages, this one is not disease-specific. Rather, this is meant to be a gathering point for all stem cell mobilization regimens.
11 regimens on this page
13 variants on this page
|
Stem cell mobilization
These are regimens intended to mobilize stem cells, very incomplete right now but will be filled in over time.
Cyclophosphamide & G-CSF
back to top |
Regimen #1
Study | Evidence |
---|---|
Oakervee et al. 2005 | Phase II |
Chemotherapy
- Cyclophosphamide (Cytoxan) 1500 mg/m2 IV once on day 1
Growth factor therapy
- Lenograstim (Granocyte) 263 mcg SC once per day starting on day 4
Stem cell collection begins on day 10 and continues until at least 2 × 106 CD34+ cells/kg are collected.
Regimen #2
Study | Evidence |
---|---|
Royer et al. 2016 | Phase II |
Chemotherapy
- Cyclophosphamide (Cytoxan) 3000 mg/m2 IV once
Growth factor therapy
- Filgrastim (Neupogen) 10 mcg/kg SC once per day and continued until at least 4 × 106 CD34+ cells/kg are collected
References
- Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. link to original article contains verified protocol PubMed
- Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. link to original article contains protocol PubMed
Cytarabine & G-CSF
back to top |
Regimen
Study | Evidence |
---|---|
Abrey et al. 2003 | Phase II |
Chemotherapy
- Cytarabine (Cytosar) 3000 mg/m2 IV once per day on days 1 & 2
Growth factor therapy
- Filgrastim (Neupogen) 10 mcg/kg SC once per day starting on day 4 and continued until stem cell collection complete
References
- Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6. link to original article contains verified protocol PubMed
Cytarabine, Ifosfamide, G-CSF
back to top |
Regimen
Study | Evidence |
---|---|
Colombat et al. 2006 | Phase II |
Chemotherapy
- Cytarabine (Cytosar) 1000 mg/m2 IV Q12H on days 1 & 2
- Ifosfamide (Ifex) 1500 mg/m2 IV once per day on days 1 to 3
Growth factor therapy
- Filgrastim (Neupogen) (dose/frequency not specified)
References
- Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. link to original article contains verified protocol PubMed
CYVE & G-CSF
back to top |
CYVE: CYtarabine, VEpesid (Etoposide)
Regimen
Study | Evidence |
---|---|
Soussain et al. 2001 | Pilot, >20 pts |
Soussain et al. 2008 | Phase II |
Target collection dose not described; mobilization took place after the first course of CYVE salvage for CNS lymphoma.
Chemotherapy
- Cytarabine (Cytosar) as follows:
- 2000 mg/m2 IV over 3 hours once per day on days 2 to 5
- 50 mg/m2 IV over 12 hours once per day on days 1 to 5
- Etoposide (Vepesid) 200 mg/m2 IV over 2 hours once per day on days 2 to 5
Growth factor therapy
- Filgrastim (Neupogen) 5 mcg/kg SC once per day starting 48 hours after end of chemotherapy
References
- Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001 Feb 1;19(3):742-9. link to original article contains verified protocol PubMed
- Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. Epub 2008 Apr 14. link to original article contains verified protocol PubMed
EAR & G-CSF
back to top |
EAR: Etoposide, Ara-C (Cytarabine), Rituximab
Regimen
Study | Evidence |
---|---|
Damon et al. 2009 (CALGB 59909) | Phase II |
Note: Text specified that PJP prophylaxis started during mobilization --although table 1 did not list it-- to continue until 3 months after auto HSCT.
Preceding treatment
- R-M-CHOP x 2 to 3 cycles
Chemotherapy
- Etoposide (Vepesid) 10 mg/kg/day IV continuous infusion over 96 hours on days 1 to 4 (total dose: 40 mg/kg)
- Cytarabine (Cytosar) 2000 mg/m2 IV over 2 hours BID on days 1 to 4 (8 total doses)
- Rituximab (Rituxan) 375 mg/m2 IV once per day on days 6 & 13
Supportive medications
- Filgrastim (Neupogen) 10 mcg/kg SC once per day starting on day 14, to continue until peripheral blood stem cell collection is complete
- Levofloxacin (Levaquin) 500 mg PO once per day, starting on day 7, to continue until ANC greater than or equal to 500/uL
- Fluconazole (Diflucan) 200 mg PO once per day, starting on day 6, to continue until ANC greater than or equal to 500/uL
- Acyclovir (Zovirax) 200 mg PO TID, starting on day 6, to continue until 1 year after auto HSCT
- Trimethoprim/Sulfamethoxazole (Bactrim DS) prophylaxis
Daily leukapheresis to start when WBC count greater than or equal to 5 x 109/L
Patients with adequate collection and meeting criteria proceeded to CBV with autologous HSCT.
References
- Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20;27(36):6101-8. Epub 2009 Nov 16. link to original article contains protocol link to PMC article PubMed
IGEV & G-CSF
back to top |
IGEV: Ifosfamide, GEmcitabine, Vinorelbine
Regimen
Study | Evidence |
---|---|
Magagnoli et al. 2007 | Phase II |
Chemotherapy
- Ifosfamide (Ifex) 2000 mg/m2 IV over 2 hours once per day on days 1 to 4
- Gemcitabine (Gemzar) 800 mg/m2 IV once per day on days 1 & 4
- Vinorelbine (Navelbine) 20 mg/m2 IV once on day 1
- Prednisolone (Millipred) 100 mg PO once per day on days 1 to 4
Supportive medications
- Mesna (Mesnex) 900 mg/m2 IV at 0, 2, 4 hours after Ifosfamide (Ifex) on days 1 to 4
- Lenograstim (Granocyte) 263 mcg SC once per day on days 7 until at least 3 x 106 CD34+ cells per kg of body weight were collected
Apheresis was performed when the peripheral blood CD34+ cell count exceeded 10 cells/ul.
References
- Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant. 2007 Dec;40(11):1019-25. Epub 2007 Oct 1. link to original article contains verified protocol PubMed
DexaBEAM & G-CSF
back to top |
DexaBEAM: Rituximab, Dexamethasone, BiCNU (Carmustine), Etoposide, Ara-C (Cytarabine), Melphalan
Regimen
Study | Evidence |
---|---|
Dreyling et al. 2004 | Non-randomized portion of RCT |
Chemotherapy
- Dexamethasone (Decadron) 8 mg PO TID on days 1 to 10
- Carmustine (BiCNU) 60 mg/m2 IV once on day 2
- Etoposide (Vepesid) 75 mg/m2 IV once per day on days 4 to 7
- Cytarabine (Cytosar) 100 mg/m2 IV BID on days 4 to 7
- Melphalan (Alkeran) 20 mg/m2 IV once on day 3
Growth factor therapy
- G-CSF starting on day 11
A minimum of 1 × 106 CD34+ cells/kg are collected.
References
- Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. link to original article contains verified protocol PubMed